FY2026 Earnings Estimate for Corcept Therapeutics Incorporated (NASDAQ:CORT) Issued By Zacks Research

Corcept Therapeutics Incorporated (NASDAQ:CORT) – Stock analysts at Zacks Research increased their FY2026 earnings per share estimates for shares of Corcept Therapeutics in a report issued on Wednesday, September 25th. Zacks Research analyst K. Das now anticipates that the biotechnology company will post earnings per share of $2.11 for the year, up from their prior estimate of $2.09. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.12 per share.

Several other research analysts also recently commented on CORT. Canaccord Genuity Group restated a “buy” rating and set a $38.00 price objective on shares of Corcept Therapeutics in a report on Tuesday, July 30th. HC Wainwright raised their price objective on Corcept Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Piper Sandler raised their price objective on Corcept Therapeutics from $38.00 to $67.00 and gave the stock an “overweight” rating in a report on Wednesday, September 18th. Finally, Truist Financial raised their price objective on Corcept Therapeutics from $65.00 to $76.00 and gave the stock a “buy” rating in a report on Monday. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Corcept Therapeutics presently has an average rating of “Buy” and a consensus target price of $56.50.

Corcept Therapeutics Stock Performance

Shares of CORT stock opened at $46.75 on Monday. The stock has a 50 day moving average price of $36.63 and a 200 day moving average price of $30.93. The firm has a market capitalization of $4.87 billion, a P/E ratio of 44.10 and a beta of 0.45. Corcept Therapeutics has a 52-week low of $20.84 and a 52-week high of $47.71.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Monday, July 29th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.09. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The firm had revenue of $163.80 million during the quarter, compared to analyst estimates of $155.14 million. During the same period last year, the company earned $0.25 EPS. Corcept Therapeutics’s quarterly revenue was up 39.1% compared to the same quarter last year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BNP Paribas Financial Markets grew its stake in Corcept Therapeutics by 199.0% during the 1st quarter. BNP Paribas Financial Markets now owns 211,592 shares of the biotechnology company’s stock worth $5,330,000 after buying an additional 140,815 shares during the last quarter. Quantedge Capital Pte Ltd acquired a new stake in Corcept Therapeutics during the 4th quarter worth about $8,066,000. Oak Ridge Investments LLC acquired a new stake in Corcept Therapeutics during the 2nd quarter worth about $984,000. Norges Bank acquired a new stake in Corcept Therapeutics during the 4th quarter worth about $24,603,000. Finally, State Board of Administration of Florida Retirement System lifted its position in Corcept Therapeutics by 190.0% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 66,866 shares of the biotechnology company’s stock worth $1,684,000 after acquiring an additional 43,809 shares during the period. 93.61% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other news, insider William Guyer sold 10,000 shares of Corcept Therapeutics stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $38.67, for a total value of $386,700.00. Following the transaction, the insider now directly owns 6,039 shares in the company, valued at approximately $233,528.13. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider William Guyer sold 10,000 shares of the business’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $38.67, for a total transaction of $386,700.00. Following the transaction, the insider now directly owns 6,039 shares in the company, valued at approximately $233,528.13. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Gary Charles Robb sold 11,000 shares of the business’s stock in a transaction on Tuesday, October 1st. The stock was sold at an average price of $46.28, for a total value of $509,080.00. Following the transaction, the insider now owns 22,772 shares in the company, valued at $1,053,888.16. The disclosure for this sale can be found here. In the last three months, insiders have sold 34,251 shares of company stock worth $1,365,292. 20.50% of the stock is currently owned by company insiders.

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.